Adaptive Biotechnologies 관리
관리 기준 확인 2/4
Adaptive Biotechnologies CEO는 Chad Robins, Sep2009 에 임명되었습니다 의 임기는 15.17 년입니다. 총 연간 보상은 $ 8.90M, 7.4% 로 구성됩니다. 7.4% 급여 및 92.6% 보너스(회사 주식 및 옵션 포함). 는 $ 8.51M 가치에 해당하는 회사 주식의 1.23% 직접 소유합니다. 8.51M. 경영진과 이사회의 평균 재임 기간은 각각 6.2 년과 8.8 년입니다.
주요 정보
Chad Robins
최고 경영자
US$8.9m
총 보상
| CEO 급여 비율 | 7.4% |
| CEO 임기 | 15.2yrs |
| CEO 소유권 | 1.2% |
| 경영진 평균 재임 기간 | 6.2yrs |
| 이사회 평균 재임 기간 | 8.8yrs |
최근 관리 업데이트
Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
보상 대 시장: Chad 의 총 보상 ($USD 8.90M )은 US 시장( $USD 3.17M ).
보상과 수익: 회사가 수익성이 없는 동안 Chad 의 보상이 증가했습니다.
CEO
Chad Robins (50 yo)
15.2yrs
테뉴어
US$8,904,267
보상
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 8.5m | |
| President & COO | 6.8yrs | US$2.97m | 0.32% $ 2.2m | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$8.61m | 0.69% $ 4.8m | |
| Chief Commercial Officer of Immune Medicine | 6.8yrs | US$2.88m | 0.22% $ 1.5m | |
| Founder | no data | 데이터 없음 | 데이터 없음 | |
| VP, CFO & Principal Accounting Officer | 3.1yrs | US$1.66m | 0.10% $ 723.8k | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 5.6yrs | 데이터 없음 | 0.17% $ 1.2m | |
| Chief Commercial Officer of MRD | 4.3yrs | 데이터 없음 | 0.17% $ 1.2m | |
| Senior Vice President of MRD BioPharma | 1.2yrs | 데이터 없음 | 데이터 없음 |
6.2yrs
평균 재임 기간
50yo
평균 연령
경험이 풍부한 관리: ADPT 의 관리팀은 노련하고 경험 (평균 재직 기간 6.2 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 8.5m | |
| Lead Independent Director | 10.9yrs | US$355.00k | 0.093% $ 647.1k | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.7yrs | US$330.00k | 0.035% $ 243.6k | |
| Independent Director | 11.8yrs | US$325.00k | 0.051% $ 356.3k | |
| Independent Director | 6.8yrs | US$310.00k | 0.037% $ 254.6k | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.7yrs | US$310.00k | 0.038% $ 263.2k |
8.8yrs
평균 재임 기간
58.5yo
평균 연령
경험이 풍부한 이사회: ADPT 의 이사회는 경험(평균 재직 기간 8.8 년)으로 간주됩니다.